According to science.org, the National Institutes of Health is ending its long-running practice of establishing public threshold scores for grant approvals across all 27 institutes and centers. The policy change, announced November 21 and taking effect in January 2026, eliminates paylines that many researchers relied on to predict funding likelihood. Instead, NIH institutes must now consider additional factors including institutional priorities, applicant career stage, existing funding, and geographic location. The shift has drawn concern from scientists like Nobel Prize winner Carol Greider about transparency and potential political influence. About half of NIH institutes, mostly smaller ones, already didn’t use public paylines.
The transparency vs flexibility debate
Here’s the thing about paylines – they gave researchers a clear target. If your grant scored in the top 10th or 16th percentile at a particular institute, you knew you were likely getting funded. That transparency is now gone. But the reality is, as DrugMonkey points out, many institutes were already making exceptions and funding grants outside paylines based on strategic priorities. The question isn’t whether exceptions should exist – it’s who gets to decide them and how transparent that process will be.
Why everyone’s worried about politics
Look, the timing here is suspicious. We’ve got a Trump administration that hasn’t exactly been science-friendly, and now they’re removing one of the most objective measures in grant funding. Jeremy Berg, former director of NIGMS, wrote on Bluesky that his comfort level “changes if directors are not selected carefully, without overt political considerations.” And he’s pointing to real red flags – like the appointment of a close friend of Vice President JD Vance to lead NIEHS, and apparently skipping search committees for about a dozen open director positions. When you combine that with program officer Jenna Norton being placed on administrative leave after speaking out… well, it doesn’t look great.
The geographic balance wild card
One of the most interesting parts of this new policy is the explicit mention of “geographic balance of funding.” Basically, NIH wants to spread research dollars beyond the usual elite coastal institutions. And honestly? That’s probably a good goal. But how do you implement it fairly? NIH was already working on revised peer-review criteria to de-emphasize institutional prestige. Now they’re adding location as a factor. The challenge is doing this without creating new forms of bias or making the process even more opaque.
What this means for scientists
For researchers, this creates massive uncertainty. As one anonymous NIH institute official told ScienceInsider, “the absence of a payline creates enormous uncertainty and anxiety for the applicants.” Imagine spending months on a grant application and having no clear benchmark for success. The peer review scores will still exist – study sections aren’t going away – but the final decision becomes much harder to predict. And with NIH’s $32 billion research budget at stake, that uncertainty could reshape entire careers and research programs. The real test will come in 2026 when we see how these new “holistic” decisions actually play out.
